Esomeprazole Magnesium (Nexium) 20 and 40 mg tablets: Innovator Astra settled patent litigation with Teva

Innovator Astra settled patent litigation with Teva pending in the U.S. District Court for the District of New Jersey

After first settling with first paara IV filer Ranabxy in April, 2008, innovator M/S AstraZeneca has entered into a licensing agreement with generic player Teva and as per terms of the settlement Teva would be able to launch the generic version in May 27, 2014 (after the expiry of two key Orange Book listed patents US5877192 and US6875872), onwards.

Teva has admitted the validity of following Orange Book patents:

US5,690,960

US5,714,504

US5,877,192

US5,900,424

US5,948,789

US6,428,810

US6,369,085

US6,875,872

US7,411,070

The other generic players like Sandoz, Dr. Reddy's and Lupin are in patent litigation with innovator, the litigation is pending in New Jersey District Court.

Paragraph IV Patent Certifications Reported by USFDA as of December 22, 2009

1. Amlodipine Besylate and Atorvastatin Calcium (Caudet) 2.5 mg + 40 mg Tablets: Para IV filed on Sep 17, 2009

2. Arformoterol Tartrate (Brovana) Eq. 0.015 mg base/2 mL Inhalation Solution: Para IV filed on Oct 1, 2009

3. Niacin and Simvastatin (Simcor)1000 mg + 20 mg Extended-release Tablets: Para IV filed on Sep 17, 2009

4. Vardenafil Hydrochloride (Levitra) 2.5 mg Tablets: Para IV filed on Sep 4, 2009

Source: USFDA Para IV certification list Here